The NIH-led trial will assess 3 drugs: infliximab, a tumor necrosis factor blocker, abatacept, a selective T cell costimulation modulator, and cenicriviroc, an investigational immunomodulator that blocks 2 chemokine receptors, CCR2 and CCR5.
The US emergency sick leave provision in the Families First Coronavirus Response Act was a highly effective policy tool to flatten the curve in the short run.
Point-of-care testing is associated with large reductions in the time to results for patients presenting with suspected COVID-19.
So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
Researchers conducted an observational, prospective, multicentric study to assess the possible relationship between granulocytic markers and COVID-19 infection and severity.
An interim analysis of the phase 2 study evaluated the combination therapy in recently diagnosed patients with mild to moderate COVID-19.
Deaths related to SARS-CoV-2 infection appear to be highest in patients older than 50 years as well as in men and patients with higher comorbidity burden.
Only 51% of Americans would get a COVID-19 vaccine, while 45% would not even try, a new poll shows.
A retrospective cohort study was used to identify patients with both psoriasis and a positive COVID-19 RT-PCR from March through May 2020.
Pandemic-induced impairments in work and social functioning are strongly correlated with elevated depression and anxiety symptoms and with decreased psychological well-being.
